M I Gaitán1, P Yañez2, M E Paday Formenti2, I Calandri3, E Figueiredo4, P Sati5, J Correale6. 1. From the Department of Neurology (M.I.G., J.C.), Neuroimmunolgy Section minesgaitan@gmail.com migaitan@fleni.org.ar. 2. Departments of Radiology (P.Y., M.E.P.F.). 3. Neurology (I.C.), FLENI, Buenos Aires, Argentina. 4. GE healthcare (E.F.), Sao Paulo, Brazil. 5. Translational Neuroradiology Section (P.S.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland. 6. From the Department of Neurology (M.I.G., J.C.), Neuroimmunolgy Section.
Abstract
BACKGROUND AND PURPOSE: Multiple sclerosis lesions develop around small veins that are radiologically described as the so-called central vein sign. With 7T MR imaging and magnetic susceptibility-based sequences, the central vein sign has been observed in 80%-100% of MS lesions in patients' brains. However, a lower proportion ∼50% has been reported at 3T using susceptibility-weighted angiography (SWAN). Our aim was to assess a modified version of SWAN optimized at 3T for sensitive detection of the central vein sign. MATERIALS AND METHODS: Thirty subjects with MS were scanned on a 3T clinical MR imaging system. 3D T2-weighted FLAIR and optimized 3D SWAN called SWAN-venule, were acquired after injection of a gadolinium-based contrast agent. Patients showing >3 focal white matter lesions were included. The central vein sign was recorded by 2 trained raters on SWAN-venule images in the supratentorial brain. RESULTS: Twenty patients showing >3 white matter lesions were included. A total of 380 white matter lesions (135 periventricular, 144 deep white matter, and 101 juxtacortical) seen on both FLAIR and SWAN-venule images were analyzed. Overall, the central vein sign was detected in 86% of the white matter lesions (periventricular, 89%; deep white matter, 95%; and juxtacortical, 78%). CONCLUSIONS: The SWAN-venule technique is an optimized MR imaging sequence for highly sensitive detection of the central vein sign in MS brain lesions. This work will facilitate the validation and integration of the central vein sign to increase the diagnostic certainty of MS and further prevent misdiagnosis in clinical practice.
BACKGROUND AND PURPOSE:Multiple sclerosis lesions develop around small veins that are radiologically described as the so-called central vein sign. With 7T MR imaging and magnetic susceptibility-based sequences, the central vein sign has been observed in 80%-100% of MS lesions in patients' brains. However, a lower proportion ∼50% has been reported at 3T using susceptibility-weighted angiography (SWAN). Our aim was to assess a modified version of SWAN optimized at 3T for sensitive detection of the central vein sign. MATERIALS AND METHODS: Thirty subjects with MS were scanned on a 3T clinical MR imaging system. 3D T2-weighted FLAIR and optimized 3D SWAN called SWAN-venule, were acquired after injection of a gadolinium-based contrast agent. Patients showing >3 focal white matter lesions were included. The central vein sign was recorded by 2 trained raters on SWAN-venule images in the supratentorial brain. RESULTS: Twenty patients showing >3 white matter lesions were included. A total of 380 white matter lesions (135 periventricular, 144 deep white matter, and 101 juxtacortical) seen on both FLAIR and SWAN-venule images were analyzed. Overall, the central vein sign was detected in 86% of the white matter lesions (periventricular, 89%; deep white matter, 95%; and juxtacortical, 78%). CONCLUSIONS: The SWAN-venule technique is an optimized MR imaging sequence for highly sensitive detection of the central vein sign in MS brain lesions. This work will facilitate the validation and integration of the central vein sign to increase the diagnostic certainty of MS and further prevent misdiagnosis in clinical practice.
Authors: Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman Journal: Nat Rev Neurol Date: 2015-09-15 Impact factor: 42.937
Authors: Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen Journal: Lancet Neurol Date: 2017-12-21 Impact factor: 44.182
Authors: Rosa Cortese; Lise Magnollay; Carmen Tur; Khaled Abdel-Aziz; Anu Jacob; Floriana De Angelis; Marios C Yiannakas; Ferran Prados; Sebastien Ourselin; Tarek A Yousry; Frederik Barkhof; Olga Ciccarelli Journal: Neurology Date: 2018-03-07 Impact factor: 9.910
Authors: Iris D Kilsdonk; Mike P Wattjes; Alexandra Lopez-Soriano; Joost P A Kuijer; Marcus C de Jong; Wolter L de Graaf; Mandy M A Conijn; Chris H Polman; Peter R Luijten; Jeroen J G Geurts; Mirjam I Geerlings; Frederik Barkhof Journal: Eur Radiol Date: 2013-12-09 Impact factor: 5.315
Authors: Iris D Kilsdonk; Alexandra Lopez-Soriano; Joost P A Kuijer; Wolter L de Graaf; Jonas A Castelijns; Chris H Polman; Peter R Luijten; Jeroen J J G Geurts; Frederik Barkhof; Mike P Wattjes Journal: J Neurol Date: 2014-04-29 Impact factor: 4.849
Authors: Pascal Sati; Jiwon Oh; R Todd Constable; Nikos Evangelou; Charles R G Guttmann; Roland G Henry; Eric C Klawiter; Caterina Mainero; Luca Massacesi; Henry McFarland; Flavia Nelson; Daniel Ontaneda; Alexander Rauscher; William D Rooney; Amal P R Samaraweera; Russell T Shinohara; Raymond A Sobel; Andrew J Solomon; Constantina A Treaba; Jens Wuerfel; Robert Zivadinov; Nancy L Sicotte; Daniel Pelletier; Daniel S Reich Journal: Nat Rev Neurol Date: 2016-11-11 Impact factor: 42.937